TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1976938

Group type: EXPERIMENTAL
Intervention: Bai‐Lin Tea
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Grapefruit Pill
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Natural Vitality pill
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Meal replacement or dietary modification
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Commercial slimming clubs
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo diet
Number of subjects: 352
Study: 24646

Group type: EXPERIMENTAL
Intervention: Lorazepam (mean dose of approximately 3 mg on a b.i.d. regimen)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31755140

Group type: EXPERIMENTAL
Intervention: R with HP
Number of subjects: 64

Group type: COMPARATOR
Intervention: NR with HP
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: R with PI
Number of subjects: 64

Group type: COMPARATOR
Intervention: NR with PI
Number of subjects: 64
Study: 31554389

Group type: EXPERIMENTAL
Intervention: Health Belief Model Questionnaire for Breast Self-examination and Screening Mammogram
Number of subjects: 103
Study: 28391283

Group type: EXPERIMENTAL
Intervention: Soy drink (250 mL, 12 mg isoflavones)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Decaffeinated black tea (300 mL, 67 mg catechins)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Water (300 mL, control)
Number of subjects: 44
Study: 25811794

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1800 mg once-daily
Number of subjects: 556
Study: 23902431

Group type: EXPERIMENTAL
Intervention: Cynatine(®) HNS (500 mg keratin plus vitamins and minerals)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 50
Study: 21478243

Group type: EXPERIMENTAL
Intervention: Group Curriculum (GC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 39
Study: 19046856

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (IVIP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Support Services
Number of subjects: 100
Study: 16919107

Group type: EXPERIMENTAL
Intervention: Maltodextrin drink
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fasted
Number of subjects: 36
Study: 15310577

Group type: EXPERIMENTAL
Intervention: Sports massage applied to one leg for 3 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control leg (no massage)
Number of subjects: 16
Study: 11222890

Group type: EXPERIMENTAL
Intervention: Metal-backed tibial component
Number of subjects: 42

Group type: COMPARATOR
Intervention: All-polyethylene tibial component
Number of subjects: 42
Study: 9052344

Group type: EXPERIMENTAL
Intervention: Fast pathway (F-F)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Slow pathway (S-S)
Number of subjects: 17
Study: 8279842

Group type: EXPERIMENTAL
Intervention: Surgical adjuvant chemotherapy for colorectal cancer; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable; control group details not available.
Number of subjects: 0
Study: 3548934

Group type: EXPERIMENTAL
Intervention: Geriatric consultation service
Number of subjects: 113

Group type: COMPARATOR
Intervention: No geriatric consultation service (Control)
Number of subjects: 113
Study: 29036016

Group type: EXPERIMENTAL
Intervention: Multimodal supervised aerobic, resistance, and flexibility exercises (EX; n = 28) for 3 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (CON; n = 29) for 3 months
Number of subjects: 57
Study: 27027416

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30)
Number of subjects: 518
Study: 24102976

Group type: EXPERIMENTAL
Intervention: Urologists performing IPG placement after stage I testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gynecologists performing IPG placement after stage I testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gynecologists performing battery placement after percutaneous testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urologists performing battery placement after percutaneous testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients treated by high-volume providers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients treated by low-volume providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Women undergoing SNM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Men undergoing SNM
Number of subjects: 0
Study: 21982737

Group type: EXPERIMENTAL
Intervention: Extensive ultrasound protocols including measurement from the carotid bifurcation and internal carotid artery
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Reduced number of angles in ultrasound protocols
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Reduced number of sites in ultrasound protocols
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 94
Study: 20079369

Group type: EXPERIMENTAL
Intervention: Worksite intervention program including enhancement of physical activity facilities, increased availability of and lower prices on healthy vending machine choices, and group behavioral programs.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 18270817

Group type: EXPERIMENTAL
Intervention: General anesthetic with propofol induction and maintenance
Number of subjects: 26

Group type: COMPARATOR
Intervention: General anesthetic with thiopental induction and isoflurane maintenance
Number of subjects: 26
Study: 15797167

Group type: EXPERIMENTAL
Intervention: RAVLT combined indices (true recognition + implicit memory score + automatic memory score)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standard RAVLT administration (true recognition + primacy recognition)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard recognition score
Number of subjects: 61
Study: 11817496

Group type: EXPERIMENTAL
Intervention: Lisuride for 6 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Anticraving drug expectancy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dopaminergic responsivity to apomorphine stimulation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 120
Study: 10519493

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 100
Study: 7554698

Group type: EXPERIMENTAL
Intervention: Chloroguanide (200 mg orally)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Chloroguanide with omeprazole (40 mg/day for 7 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mephenytoin (100 mg orally)
Number of subjects: 20
Study: 2202384

Group type: EXPERIMENTAL
Intervention: Zabicipril 2.5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Zabicipril (0.03 to 10 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Zabicipril
Number of subjects: 42
Study: 7261552

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg b.i.d.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg b.i.d.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29350459

Group type: EXPERIMENTAL
Intervention: NOURISH-T intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 0
Study: 26891648

Group type: EXPERIMENTAL
Intervention: Kinesiology tape (EG1, from origin to insertion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Kinesiology tape (EG2, from insertion to origin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24820681

Group type: EXPERIMENTAL
Intervention: Static medial load for varus knees
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static tibiofemoral alignment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic medial load distributions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Static plateau load distributions
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Dynamic medial load
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tibiofemoral angle
Number of subjects: 15
Study: 22828124

Group type: EXPERIMENTAL
Intervention: saxagliptin 2.5 mg q.A.M.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg q.A.M.
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg q.P.M.
Number of subjects: 365

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: saxagliptin (all doses)
Number of subjects: 365

Group type: COMPARATOR
Intervention: control (placebo)
Number of subjects: 365
Study: 20980999

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg with high-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg with low-fat meal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pazopanib 400 mg with high-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pazopanib in fasting condition
Number of subjects: 0
Study: 18927270

Group type: EXPERIMENTAL
Intervention: Immobilization for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recovery for 2 weeks after immobilization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remobilization for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic concentrations of PINP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 0
Study: 15793044

Group type: EXPERIMENTAL
Intervention: Intraoperative hemofiltration (HF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional treatment (CONV)
Number of subjects: 80
Study: 11952027

Group type: EXPERIMENTAL
Intervention: Emedastine plus placebo capsules
Number of subjects: 80

Group type: COMPARATOR
Intervention: Loratadine plus placebo eyedrops
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combination of emedastine and loratadine
Number of subjects: 80
Study: 10551714

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (1 g bid, p.o.)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine
Number of subjects: 485
Study: 8635265

Group type: EXPERIMENTAL
Intervention: TAK-044 (10 to 1000 mg IV over a 15-minute period)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TAK-044 (30, 250, and 750 mg IV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: TAK-044 (1000 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 1947791

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg three times daily for 6 days
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo three times daily for 6 days
Number of subjects: 339
Study: 6339137

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chymopapain injection (4000 IU, 2 ml)
Number of subjects: 29
Study: 30630860

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28763356

Group type: EXPERIMENTAL
Intervention: Multiport wire-reinforced flexible catheter
Number of subjects: 650

Group type: COMPARATOR
Intervention: Uniport wire-reinforced flexible catheter
Number of subjects: 650
Study: 28479899

Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: nicardipine+esmolol
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: nitroglycerin
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: nitroglycerin+esmolol
Number of subjects: 340

Group type: COMPARATOR
Intervention: control (Group E)
Number of subjects: 340
Study: 26460907

Group type: EXPERIMENTAL
Intervention: Individualized educational program
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional information
Number of subjects: 207
Study: 22410480

Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (1 Hz)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Priming rTMS (6 Hz)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 54
Study: 21316537

Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg BID orally after a loading dose of 400 mg BID on day 1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Itraconazole (100 mg BID orally, no loading dose)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Voriconazole and Itraconazole
Number of subjects: 53
Study: 18553458

Group type: EXPERIMENTAL
Intervention: R1626 500 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: R1626 1500 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: R1626 3000 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: R1626 4500 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 16491958

Group type: EXPERIMENTAL
Intervention: SCDSF treatment
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 179
Study: 12057718

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10496247

Group type: EXPERIMENTAL
Intervention: Vigabatrin monotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Carbamazepine monotherapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 32
Study: 8756741

Group type: EXPERIMENTAL
Intervention: t‐PA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PAI‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: alpha 2‐antiplasmin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: plasminogen activity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: fibrin degradation products (FDP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: euglobulin lysis time (ELT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: t‐PA and PAI‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: plasminogen and alpha 2‐AP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FDP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: examined parameters
Number of subjects: 30
Study: 1837202

Group type: EXPERIMENTAL
Intervention: McArdle's disease
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acid maltase deficiency
Number of subjects: 19
Study: 6360703

Group type: EXPERIMENTAL
Intervention: Inhalation powder (1 mg fenoterol, 5 doses of 0.2 mg over 10 minutes)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pressurized aerosol (1 mg fenoterol, 5 doses of 0.2 mg over 10 minutes)
Number of subjects: 15
Study: 30449623

Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 on days 1, 22, and 43 of radiotherapy)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m2 loading dose followed by seven weekly infusions of 250 mg/m2)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 334

Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 334
Study: 29959763

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone replacement therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: No recombinant human growth hormone replacement therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Surgical treatment and cranial radiotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Interferon‐α exclusively
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: General treatment outcomes
Number of subjects: 57
Study: 26861603

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for 5 years
Number of subjects: 360

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 360
Study: 24402594

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (clear liquid diet and two self-administered saline enemas)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Regular diet and nothing by mouth after midnight (Control)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 150
Study: 21922153

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus Paclitaxel (GT)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Paclitaxel monotherapy (T)
Number of subjects: 351
Study: 19116178

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin plus low-dose aspirin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 85
Study: 17439900

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFN-β 1a)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immunoglobulins (Igs)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (IFN-β 1a) and Glatiramer acetate (GA)
Number of subjects: 60
Study: 17660643

Group type: EXPERIMENTAL
Intervention: Fuji‐VII glass ionomer cement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light-cured unfilled resin
Number of subjects: 0
Study: 14751336

Group type: EXPERIMENTAL
Intervention: KNa-Cit and MgO (combined)
Number of subjects: 39

Group type: COMPARATOR
Intervention: KNa-Cit (alone)
Number of subjects: 39

Group type: COMPARATOR
Intervention: MgO (alone)
Number of subjects: 39
Study: 11207003

Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Goserelin plus Tamoxifen
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (systematically untreated)
Number of subjects: 149
Study: 9075032

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 8214530

Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thiopentone/isoflurane/alfentanil
Number of subjects: 40
Study: 3011257

Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) at 300 mg/m2
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) at 600 mg/m2
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Etoposide (VP-16) at 900 mg/m2
Number of subjects: 79
Study: 31550381

Group type: EXPERIMENTAL
Intervention: Goal setting and attainment intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Resource program contacts
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Goal track
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 28864675

Group type: EXPERIMENTAL
Intervention: G-tube placement
Number of subjects: 481
Study: 25977146

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole 320 mg/1600 mg twice daily
Number of subjects: 252

Group type: COMPARATOR
Intervention: Vancomycin 1 g twice daily
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Trimethoprim‐sulfamethoxazole
Number of subjects: 252

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 252
Study: 23686085

Group type: EXPERIMENTAL
Intervention: Tourniquet group (T group)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No tourniquet group (NT group)
Number of subjects: 51
Study: 21132308

Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19438487

Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation (MEA)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Transcervical resection of the endometrium (TCRE)
Number of subjects: 263
Study: 16732143

Group type: EXPERIMENTAL
Intervention: One dose of dexamethasone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Three daily doses of dexamethasone
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 15465501

Group type: EXPERIMENTAL
Intervention: Tai chi training (1‐hour class held twice weekly for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (pharmacologic therapy and dietary and exercise counseling)
Number of subjects: 30
Study: 11394516

Group type: COMPARATOR
Intervention: Lidocaine 5% (100 mg in 7.5% glucose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Procaine 10% (100 mg diluted with 1 ml cerebrospinal fluid)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Procaine 10%
Number of subjects: 60
Study: 9555823

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream containing polyolprepolymer‐2
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream (commercially available)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 271
Study: 7672871

Group type: EXPERIMENTAL
Intervention: Amikacin (15 mg/kg per day) given in one (qd, n = 10) or two equal injections (b.i.d., n = 12) for durations of 7‐11 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (healthy neonates)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amikacin (qd and b.i.d. administration)
Number of subjects: 22
Study: 2646469

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT) with free mixtures of regular and intermediate (12 hrs)‐acting insulin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT) with basal and prandial insulin treatment (preprandial injections of regular insulin, and ultralente (24 hrs‐acting) or intermediate insulin for basal demand)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intensified insulin therapy (IIT)
Number of subjects: 52
Study: 31477497

Group type: EXPERIMENTAL
Intervention: Empagliflozin (EMPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28390403

Group type: EXPERIMENTAL
Intervention: Cost-offset community supported agriculture participation with reduced-price shares, nutrition education classes, and kitchen tools.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed intervention group (control).
Number of subjects: 0
Study: 26202150

Group type: EXPERIMENTAL
Intervention: Novel recombinant human FSH (rhFSH, FE 999049) at doses of 5·2‐12·1 μg/day
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Novel recombinant human FSH (rhFSH, FE 999049)
Number of subjects: 265